Publications - FIDMAG, Fundation for research

COOKIES USE
We use necessary system cookies for the correct functioning of the website and optional Google Analytics cookies to obtain visit statistics. +info

Cookies config

Necessary

The necessary cookies are absolutely essential for the website to work properly. This category only includes cookies that guarantee basic website security and functionality. These cookies do not store any personal information.

Name	Proveedor	Propiedad	Finalidad	Caducidad
_GRECAPTCHA	google.com	Own	provide antispam protection with the reCaptcha service	6 months
cc_cookie_accept	fidmag.org	Own	Usada per confirmar que l'usuari ha confirmat / refusat les cookies (i quins tipus accepta)	1 any
WEB_SESSION	fidmag.org	Own	Cookie técnica: cookie de sessió PHP. Guarda l'id de sessió d'usuari.	al acabar la sessió

Analisys

Analytical cookies are used to understand how visitors interact with the website. These cookies help to provide information on meters, the name of visitors, the percentage of bounces, the font of the traffic, etc.

Name	Proveedor	Propiedad	Finalidad	Caducidad
_ga	Google Analytics	From third parties	Cookie d'anàlisi o mesurament: Identifica els usuaris i proporciona informació sobre com els usuaris troben la pàgina web i com la utilitzen per a realització d'Informes estadístics	2 anys
_gat_gtag_UA_141706552_1	Google Analytics	From third parties	Cookie d'anàlisi o mesurament: Tracking per part de google per google analytics	1 minut
_gid	Google Analytics	From third parties	Cookie d'anàlisi o mesurament: S'usa per limitar el percentatge de sol·licituds	24 hores

Configure Reject all Accept

Home
> Research

Back to results

FI
14.496

24492349

2014 Molecular Psychiatry

APOE2 enhances neuroprotection against Alzheimer's disease through multiple molecular mechanisms.

Conejero-Goldberg C, Gomar JJ, Bobes-Bascaran T, Hyde TM, Kleinman JE, Herman MM, Chen S, Davies P, Goldberg TE

Limited service to collaborators of the network of Sisters Hospitalarias Centers. You will receive a message in your email with a link to download this article.

Abstract

The common APOE2 gene variant is neuroprotective against Alzheimer's disease (AD) and reduces risk by nearly 50%. However, the mechanisms by which APOE2 confers neuroprotection are largely unknown. Here we showed that ApoE protein abundance in human postmortem cortex follows an isoform-dependent pattern (E2>E3>E4). We also identified a unique downstream transcriptional profile determined by microarray and characterized by downregulation of long-term potentiation (LTP) related transcripts and upregulation of extracellular matrix (ECM)/integrin-related transcripts in E2 cases and corroborated this finding at the protein level by demonstrating increases in ECM collagens and laminins. In vivo studies of healthy older individuals demonstrated a unique and advantageous biomarker signature in E2 carriers. APOE2 also reduced the risk of mild cognitive impairment to AD conversion by half. Our findings suggest that ApoE2 protein abundance, coupled with its inability to bind to LDLRs, may act to increase amyloid-beta (Ab) clearance. In addition, increased ECM and reduced LTP-related expression results in diminished activity-dependent Ab secretion and/or excitotoxicity, and thus also promotes neuroprotection.Molecular Psychiatry advance online publication, 4 February 2014; doi:10.1038/mp.2013.194.